Benefits
Mast cell and inflammatory mediators
In lab studies, luteolin blocks mast cell activation and the release of inflammatory mediators. Human data are limited: in an open-label study of 40 children with autism given a luteolin, quercetin and rutin formula for 26 weeks, serum IL-6 and TNF fell from baseline, with no placebo group. In a small placebo-controlled crossover in veterans with Gulf War illness, luteolin alone did not reduce symptoms.
Antioxidant activity (lab studies)
Lab studies describe luteolin as a radical scavenger with cell-protective effects and less pro-oxidant potential than quercetin. After eating, luteolin is largely converted to other compounds, so lab results may not reflect what happens in the body.
Senescent cell activity in a lab screen
In a screen of 10 flavonoids in senescent mouse cells, luteolin showed weak activity at a dose where quercetin had none, while fisetin was by far the most potent. This is a lab finding only.
Mechanism of action
Mast Cell Inhibition
In lab studies, luteolin inhibits mast cell activation and the release of histamine and inflammatory cytokines that follows allergen binding.
NF-κB Pathway Inhibition
Lab studies show luteolin suppresses the NF-κB pathway and other pro-inflammatory signals and activates antioxidant enzymes, at concentrations that may be higher than those reached in the body after eating.
Clinical trials
Open-label, 26-week study of a formula with luteolin (100 mg per capsule), quercetin (70 mg) and rutin (30 mg) in olive kernel oil, 1 capsule per 10 kg of body weight daily (Taliou et al. 2013, Clin Ther)
50 children aged 4 to 10 with autism spectrum disorder enrolled; 40 completed.
Adaptive functioning and aberrant behavior scores improved from baseline; 27 of 50 children had transient irritability. A follow-up analysis of the same children found serum IL-6 and TNF fell from baseline, mainly in those whose behavior improved most. There was no placebo group, and luteolin was not tested alone.
Placebo-controlled, pseudo-randomized crossover screening trial in male veterans: 1 month placebo, then luteolin 200 mg/day and 400 mg/day for 1 month each (Hodgin et al. 2021, Int J Environ Res Public Health)
Male veterans with Gulf War illness (21 completed the wider trial; a subset took luteolin).
Luteolin did not reduce symptom severity more than placebo at either the lower (p = 0.718) or higher (p = 0.492) dose. In the same trial, resveratrol did reduce symptoms.